Name: | Secobarbital |
---|---|
PubChem Compound ID: | 30019 |
Description: | A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity. |
Molecular formula: | C12H18N2O3 |
Molecular weight: | 238.283 g/mol |
Synonyms: |
S(-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (S)- (9CI); S(-)-Secobarbital; 20224-45-7; BARBITURIC ACID, 5-ALLYL-5-(1-METHYLBUTYL)-, (S)-(-)-
|
Name: | Secobarbital |
---|---|
Name (isomeric): | DB00418 |
Drug Type: | small molecule |
Description: | A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity. |
Synonyms: |
Secobarbital Sodium; Sodium Secobarbital; Sodium quinalbarbitone; (+/-)-Secobarbital; Secobarbitale [DCIT]; Secobarbitalum [INN-Latin]
|
Brand: | Meballymal, Quinalbarbitone, Seconal, Evrronal, Barbosec, Meballymalum, Trisomnin, Bipinal sodium, Quinalbarbital, Secobarbitone, Novosecobarb, Evronal Sodium, Sedutain, Somosal, Hyptran, Imesonal, Immenoctal, Bipanal, Seco 8, Sebar, Seotal, Evronal, Pramil, Hypotrol, Quinalspan, Meballymal sodium, Immenox, Quinalbarbitone sodium, Synate |
Category: | Adjuvants, Anesthesia, GABA Modulators, Hypnotics and Sedatives, Barbiturates, Adjuvants |
CAS number: | 76-73-3 |
Indication: | For the Short-term treatment of intractable insomnia for patients habituated to barbiturates |
---|---|
Pharmacology: |
Secobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in exc...
show more » |
Mechanism of Action: | Secobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
Route of elimination: | Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces. |
Toxicity: | Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|